Ionis Pharmaceuticals Says FDA Accepts Metabolic Disorder Drug Candidate for Priority Review
Ionis Pharmaceuticals Says FDA Accepts Metabolic Disorder Drug Candidate for Priority Review
ionis pharmaceuticals稱FDA已接受代謝紊亂藥物候選品進行優先審評
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊